CBCameron R. Bastow

Cameron R. Bastow

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cameron R. Bastow has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Althea R. Suthya

    Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia

    2 shared publications
  • Connie H. Y. Wong

    Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences at Monash Health, Monash Medical Centre, Monash University, Clayton, VIC, 3168, Australia

    2 shared publications
  • Jenny L. Wilson

    Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia

    2 shared publications
  • Shu Wen Wen

    Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Australia

    2 shared publications
  • Adriana Caon

    Chemokine Biology Laboratory, Department of Molecular and Biomedical Science, School of Biological Science, The University of Adelaide, Adelaide, SA 5005, Australia

    1 shared publication
  • Brooke J. Wanrooy

    Centre for Inflammatory Diseases, Department of Medicine, School of Clinical Sciences, Monash Medical Centre, Monash University, Clayton, VIC, Australia

    1 shared publication

Latest Publications

  • Open Access

    A new murine gram-negative sepsis model with standard care satisfies Sepsis-3 and reproduces clinical pathology

    by Cameron R. Bastow, Cynthia Mei, Shu Wen Wen, Jenny L. Wilson, Huynh Nguyen, Althea R. Suthya, Joshua H. Bourne, Yugeesh R. Lankadeva, Connie H. Y. Wong

    Background: Sepsis accounts for approximately a third of global mortality, and significant morbidity and economic burden. Whilst the current Sepsis-3 definition has augmented patient identification, supportive care and survival, a lack of clinically relevant animal models has limited our understanding of sepsis disease dynamics over time. Specifically, key knowledge gaps in chronic pathology underpinning the mechanisms leading to organ dysfunction and mortality rates of sepsis survivors have hindered the development of effective therapeutics. Therefore, we developed a new mouse model of abdominal gram-negative sepsis that adheres to Sepsis-3 definitions and expert-led consensus criteria for preclinical sepsis models. Results: We tested multiple live strains of Escherichia coli with only clinical isolates causing lethality. Subsequent standard care including broad-spectrum antibiotics and fluid resuscitation reduced the mortality rate to approximately 24 ± 9.3% (SEM), corroborating clinical observations. Early sepsis disease 12 h post-infection was characterized by cytokine storm, with concentrations of IFN-γ, CCL2, IL-6, IL-17A, IL-1α, IL-10 and M-CSF significantly elevated in multiple tissues up to 7 days post-infection when mice had recovered from objective clinical measures of disease. Furthermore, we observed histological evidence of organ dysfunction in the liver, spleen and kidney at 12 h to 3 days post-infection, validating concurrently increased serum markers of organ damage in our model. Additionally, infected mice treated with standard care exhibited persistent haematological dysfunction, as evidenced by anaemia, thrombocytosis and neutrophilia, at recovery from organ dysfunction 7 days post-infection, features similarly observed in clinical sepsis patients. Conclusions: Our new abdominal gram-negative murine sepsis model recapitulates key disease outcomes observed in sepsis patients and allows the study of dysfunctional homeostasis in surviving animals. This model can be utilized to identify and test new therapeutics for abdominal gram-negative sepsis or investigate novel mechanisms of immune dysfunction in sepsis survivors. Modifications to our murine model by utilizing alternate clinical pathogens, routes of infection, and mixed-sex, outbred or aged mice are necessary to recapitulate clinical sepsis heterogeneity and address the inherent limitations of preclinical models. Here, our methodology to establish a model with clinical isolates, satisfaction of Sepsis-3 definitions and preclinical sepsis guidelines provides a framework for the development of future models.

  • Top Cited Papers
    Open Access

    Microglia are prominent producers of inflammatory cytokines during the hyperacute phase of ischemic stroke

    by Joshua H. Bourne, Althea R. Suthya, Brooke J. Wanrooy, Jenny L. Wilson, Shu Wen Wen, Cameron R. Bastow, Gang Zheng, Michelle Rank, Michael J. Hickey, Connie Hy Wong

    Current treatments for ischemic stroke focus on removing neurovascular-occluding clots but overlook the resulting neuroinflammation. Clinical trials targeting brain-infiltrating peripheral immune cells have failed to improved outcomes, leaving mechanisms of neuroinflammation poorly understood. Whilst many studies have examined the inflammatory cells and cytokine profile of the post-stroke brain at days and weeks following injury onset, we propose that interventions at these timepoints are too late to limit brain damage. In this study, we examined brain immune cell composition, cytokine levels, and neurological dysfunction at hyperacute (3 h) and acute (24 h) stages following a preclinical mouse model of ischemic stroke. Interestingly, we detected elevated inflammatory cytokines in brain tissue as early as 3 h, notably before infiltrating neutrophil and monocyte arrival at 24 h. Depletion of peripheral immune cells by antibodies or genetic alteration did not dampen neuroinflammation, nor improve sensorimotor function. Intravital imaging of Cx3cr1gfp/+ mice showed that microglia, the brain-resident immune cell, display rapidly altered morphology, and swiftly upregulated cytokine production hyperacutely post-stroke. Altogether, our study provides evidence that microglia are key drivers of early neuroinflammation and modulating their function at clinically-relevant timepoints will improve stroke recovery.


  • Scavenging of soluble and immobilized CCL21 by ACKR4 regulates peripheral dendritic cell emigration

    by Cameron R. Bastow, Mark D. Bunting, Ervin E. Kara, Duncan R. McKenzie, Adriana Caon, Sapna Devi, Lynn Tolley, Scott N. Mueller, Ian H. Frazer, Natasha Harvey, et al.

    Leukocyte homing driven by the chemokine CCL21 is pivotal for adaptive immunity because it controls dendritic cell (DC) and T cell migration through CCR7. ACKR4 scavenges CCL21 and has been shown to play an essential role in DC trafficking at the steady state and during immune responses to tumors and cutaneous inflammation. However, the mechanism by which ACKR4 regulates peripheral DC migration is unknown, and the extent to which it regulates CCL21 in steady-state skin and lymph nodes (LNs) is contested. Specifically, our previous findings that CCL21 levels are increased in LNs of ACKR4-deficient mice [I. Comerford et al., Blood 116, 4130–4140 (2010)] were refuted [M. H. Ulvmar et al., Nat. Immunol. 15, 623–630 (2014)], and no differences in CCL21 levels in steady-state skin of ACKR4-deficient mice were reported despite compromised CCR7-dependent DC egress in these animals [S. A. Bryce et al., J. Immunol. 196, 3341–3353 (2016)]. Here, we resolve these issues and reveal that two forms of CCL21, full-length immobilized and cleaved soluble CCL21, exist in steady-state barrier tissues, and both are regulated by ACKR4. Without ACKR4, extracellular CCL21 gradients in barrier sites are saturated and nonfunctional, DCs cannot home directly to lymphatic vessels, and excess soluble CCL21 from peripheral tissues pollutes downstream LNs. The results identify the mechanism by which ACKR4 controls DC migration in barrier tissues and reveal a complex mode of CCL21 regulation in vivo, which enhances understanding of functional chemokine gradient formation. Significance The immune system relies on coordinated interactions between motile cells guided by molecules known as chemokines. However, processes that control chemokine distribution in complex in vivo microenvironments are poorly understood. Dendritic cells in barrier tissues require the chemokine CCL21 to enter lymphatic vessels during tissue egress. Here, we demonstrate that ACKR4 shapes CCL21 distribution in barrier tissues and prevents leakage of CCL21 from the tissue. Without ACKR4, extracellular CCL21 gradients in barrier sites are saturated and nonfunctional, DCs cannot home directly to lymphatic vessels, and excess soluble CCL21 from peripheral tissues pollutes lymph nodes. The results increase understanding of regulation of dendritic cell egress and chemokine distribution in vivo and raise new questions regarding the function of solubilized CCL21.